Solid revenue, positive EBITDA, very low cash usage, continued market adoption of new therapy products, new FDA approvals that expand the treatment paradigm, rebounding detection revenue, and new partnerships. It looks like their strategy is beginning to pay off...looking forward to the call tomorrow.
Sorry on the call they mentioned a loss of 11 cents a share. I didn't realize that there was a 6 month delay for the system. Someone should have asked how many new orders were on the books. The nine month comparison doesn't work because they didn't have sales or reimbursement one and 1/2 years ago. So once again we get no guidance. Doesn't matter you have to go with the volume.